专利检索 ap:("Actuate Therapeutics Inc.") AND inv:"Torry A. Tucker" 第 1 页

1.

发明授权
Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form β inhibitors 有权

公开(公告)号：US12083098B2

公开(公告)日：2024-09-10

申请号：US17056238

申请日：2019-05-16

申请人： Actuate Therapeutics Inc.

发明人： Torry A. Tucker , Steven Idell

IPC分类号： A61K31/407 , A61K9/00 , A61P11/00

CPC分类号： A61K31/407 , A61K9/0073 , A61P11/00

摘要： Pharmaceutical compositions and methods are described which rely upon glycogen synthase kinase 3 (form β; GSK 3 β) inhibitors, most preferably 9-ING-41, to inhibit fibrotic pulmonary remodeling in vivo including proliferation and differentiation of myofibroblasts to fibrotic fibroblasts in several mouse models. Therapeutic targeting of GSK-3β with the clinically useful specific inhibitor, 9-ING-41, mitigates fibrotic pulmonary remodeling in vivo and provides a mode of therapy of human IPF by specific GSK-3β inhibition with 9-ING-41.